Novel therapeutic targets of metformin: Metabolic syndrome and cardiovascular disease

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 7, 2015, Pages 869-877

  Ladeiras Lopes, Ricardo ^a,b   Fontes Carvalho, Ricardo ^a,b   Bettencourt, Nuno ^a,b   Sampaio, Francisco ^a,b   Gama, Vasco ^a,b   Leite Moreira, Adelino ^b  

^a Department of Cardiology   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Cardiovascular disease; Heart failure; Ischemic heart disease; Metabolic syndrome; Metformin

Indexed keywords

ADIPOCYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; METFORMIN; NITRIC OXIDE; ANTIDIABETIC AGENT;

ACUTE CORONARY SYNDROME; ANTIDIABETIC ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DIABETIC CARDIOMYOPATHY; DIABETIC PATIENT; DRUG MECHANISM; DRUG TARGETING; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PLEIOTROPY; REPERFUSION INJURY; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; MOLECULARLY TARGETED THERAPY; MYOCARDIAL REPERFUSION INJURY; PREDIABETIC STATE;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; METFORMIN; MOLECULAR TARGETED THERAPY; MYOCARDIAL REPERFUSION INJURY; PREDIABETIC STATE;

EID: 84931061191     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1025051     Document Type: Review

References (65)

1. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014;37(Suppl 1):S14-80
2. Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia 2013;56:1898-906
3. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 2012;59:635-43
4. Fuster V. Global burden of cardiovascular disease: time to implement feasible strategies and to monitor results. J Am Coll Cardiol 2014;64:520-2
5. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-52
6. El Messaoudi S, Rongen GA, Riksen NP. Metformin therapy in diabetes: The role of cardioprotection. Curr Atheroscler Rep 2013;15:314
7. Wong AK, Struthers AD, Choy AM, et al. Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones. Heart Fail Clin 2012;8:539-50
8. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its antidiabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348 Pt 3:607-14
9. Hardie DG, Ross FA, Hawley SA. AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-62
10. Hawley SA, Ross FA, Chevtzoff C, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 2010;11:554-65
11. Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-69
12. Miller RA, Chu Q, Xie J, et al. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013;494:256-60
13. Davis BJ, Xie Z, Viollet B, et al. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006;55:496-505
14. Ouslimani N, Peynet J, Bonnefont-Rousselot D, et al. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 2005;54:829-34
15. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28
16. Salpeter SR, Buckley NS, Kahn JA, et al. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008;121:149-57.e2
17. Jellis C, Martin J, Narula J, et al. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 2010;56:89-97
18. Kosmala W, Przewlocka-Kosmala M, Wojnalowicz A, et al. Integrated backscatter as a fibrosis marker in the metabolic syndrome: association with biochemical evidence of fibrosis and left ventricular dysfunction. Eur Heart J Cardiovasc Imaging 2012;13:459-67
19. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115:3213-23
20. Stratmann B, Tschoepe D. Heart in diabetes: not only a macrovascular disease. Diabetes Care 2011;34(Suppl 2):S138-44
21. Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 2000;101:899-907
22. McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: A 1H-magnetic resonance spectroscopy study. Circulation 2007;116:1170-5
23. Eguchi K, Boden-Albala B, Jin Z, et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008;101:1787-91
24. Nakai H, Takeuchi M, Nishikage T, et al. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. Euro J Echocardiogr 2009;10:926-32
25. Zabalgoitia M, Ismaeil MF, Anderson L, et al. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 2001;87:320-3
26. Burlá AK, Lobato NS, Fortes ZB, et al. Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. Int J Cardiol 2011;165(3):483-7
27. Cittadini A, Napoli R, Monti MG, et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 2012;61:944-53
28. Xiao H, Ma X, Feng W, et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res 2010;87:504-13
29. Zhang CX, Pan SN, Meng RS, et al. Metformin attenuates ventricular hypertrophy by activating the AMP-activated protein kinase-endothelial nitric oxide synthase pathway in rats. Clin Exp Pharmacol Physiol 2011;38:55-62
30. Fontes-Carvalho R, Ladeiras-Lopes R, Bettencourt P, et al. Diastolic dysfunction in the diabetic continuum : association with insulin resistance, metabolic syndrome and type 2 diabetes. Cardiovasc Diabetol 2015;14:4
31. Ladeiras-Lopes R, Fontes-Carvalho R, Bettencourt N, et al. METformin in DIastolic Dysfunction of Metabolic syndrome (MET-DIME) trial: rationale and study design : MET-DIME trial. Cardiovasc Drugs Ther 2014;28:191-6
32. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766-81
33. Russo C, Jin Z, Homma S, et al. Effect of obesity and overweight on left ventricular diastolic function: A community-based study in an elderly cohort. J Am Coll Cardiol 2011;57:1368-74
34. Lavie CJ, Alpert MA, Arena R, et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail 2013;1:93-102
35. Powell BD, Redfield MM, Bybee KA, et al. Association of obesity with left ventricular remodeling and diastolic dysfunction in patients without coronary artery disease. J Am Coll Cardiol 2006;98:116-20
36. Patel SB, Reams GP, Spear RM, et al. Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr Hypertens Rep 2008;10:131-7
37. Taube A, Schlich R, Sell H, et al. Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol 2012;302:H2148-65
38. Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol 2013;4:71
39. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996;271:10697-703
40. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83
41. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Int Med 2005;257:167-75
42. Heiker JT, Kosel D, Beck-Sickinger AG. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol Chem 2010;391:1005-18
43. Mao X, Kikani CK, Riojas RA, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 2006;8:516-23
44. Schmid PM, Resch M, Steege A, et al. Globular and full-length adiponectin induce NO-dependent vasodilation in resistance arteries of Zucker lean but not Zucker diabetic fatty rats. Am J Hypertens 2011;24:270-7
45. Schmid PM, Resch M, Schach C, et al. Antidiabetic treatment restores adiponectin serum levels and APPL1 expression, but does not improve adiponectin-induced vasodilation and endothelial dysfunction in Zucker diabetic fatty rats. Cardiovasc Diabetol 2013;12:46
46. Evia-Viscarra ML, Rodea-Montero ER, Apolinar-Jimenez E, et al. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J Pediatr Endocrinol Metab 2012;25:41-9
47. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65
48. Calvert JW, Gundewar S, Jha S, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008;57:696-705
49. Gundewar S, Calvert JW, Jha S, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 2009;104:403-11
50. Lexis CP, Wieringa WG, Hiemstra B, et al. Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with STsegment elevation myocardial infarction. Cardiovasc Drugs Ther 2014;28:163-71
51. Bhamra GS, Hausenloy DJ, Davidson SM, et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 2008;103:274-84
52. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 2003;35:339-41
53. Paiva M, Riksen NP, Davidson SM, et al. Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol 2009;53:373-8
54. Jonassen AK, Brar BK, Mjos OD, et al. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. J Mol Cell Cardiol 2000;32:757-64
55. Jonassen AK, Sack MN, Mjos OD, et al. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001;89:1191-8
56. Gao F, Gao E, Yue TL, et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemiareperfusion: The roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation 2002;105:1497-502
57. Lexis CP, van der Horst IC, Lipsic E, et al. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: The GIPS-III randomized clinical trial. JAMA 2014;311:1526-35
58. Agarwal N, Rice SP, Bolusani H, et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: A randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010;95:722-30
59. McCoy RG, Irving BA, Soop M, et al. Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance. Mayo Clin Proc 2012;87:561-70
60. Gin H, Freyburger G, Boisseau M, et al. Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diabetes Res Clin Pract 1989;6:61-7
61. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes care 1993;16:621-9
62. Bhalla RC, Toth KF, Tan E, et al. Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am J Hypertens 1996;9:570-6
63. Landin-Wilhelmsen K. Metformin and blood pressure. J Clin Pharm Ther 1992;17:75-9
64. He H, Zhao Z, Chen J, et al. Metformin-based treatment for obesityrelated hypertension: A randomized, double-blind, placebo-controlled trial. J Hypertens 2012;30:1430-9
65. Available from: http://www.servier.com/ Powerpoint-image-bank